With TransCode going public, industry surpasses $10B IPO mark; Galectin's inhibitor shows PhIb success in cancer treatment
TransCode Therapeutics has priced its IPO at $4 a share, and while that number might be on the smaller end of IPOs this year, it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
